Therefore, LRP6 offers a promising option for therapeutic intervention in breast cancer.<h4>Aims</h4>This research aims to use in silico and bioinformatics techniques to develop an mRNA vaccine that specifically targets the LRP6 antigen.<h4>Methods and results</h4>The final vaccine construct comprised 431 amino acids, with a molecular weight of 47.5 kDa, theoretical pI of 5.11, and an instability index of 38.3 indicating stability. The gene discussed is LRP6; the disease is breast carcinoma.